17,261 trials
Melanoma Stage Iii · Melanoma Stage Iv · Melanoma
Primary: The Antitumor Effect of Denosumab Alone as Represented by the Change in Recent Thymic Emigrant Cells in Peripheral Blood — 2.69; 2.42; 2.55; 1.92 number of cell per…
Cocaine-Related Disorders · Anhedonia
Primary: Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) — 3; 3; 6 Participants
Alzheimer Disease, Early Onset
Primary: Change in Reverse Transcriptase Activity From Baseline to 24 Weeks in Plasma of Study Participants — -0.0074 Enzyme units
HIV Infections
Primary: Virological Suppression at 24 Weeks — 55; 53; 53 Participants
Diabetic Foot Ulcer
Primary: Time to New Foot Complication Among All Randomized Participants — 12; 14 Participants
Systemic Sclerosis
Primary: Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week. — -3.41; -4.22 number of attacks — p=<0.05
Pulmonary Arterial Hypertension · Right Heart Failure
Primary: Change in Six-minute Walk Distance — -17.0; 4.7 meters
Diabetic Retinopathy
Primary: Proportion of Participants Who Improved by ≥ 2 Steps From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Scores — 12.187; 12.263; 13.311 estimated improvement…
Sickle Cell Disease · Vitamin D Deficiency · Acute Chest Syndrome
Primary: Mean Annual Rate of Respiratory Events — 3.91; 4.34; 3.34; 4.28 events per year
Breast Cancer
Primary: Clinical Benefit Rate (CBR) for ZN-c5 as a Monotherapy — 7; 0; 1; 1 Participants
Cancer of the Colon · Colon Cancer · Colon Neoplasms
Primary: Disease Control Rate — 5; 1; 0; 0 Participants
Post-menopausal Vasomotor Symptoms
Primary: Peak Plasma Concentration (Cmax) of ACER-801 — 10.78; 32.36; 41.75 ng/mL
Small-cell Lung Cancer
Primary: Adverse Event — 47; 6; 5 participants
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.70; -1.81 score on a scale
Neovascular Age-related Macular Degeneration
Primary: Treatment Emergent Adverse Events (TEAEs) Will be Evaluated for Ocular and Systemic Safety and Tolerability of a Repeat IVT Injection of UBX1325 Compared to Active…